Polymorphism (-499C/G) in DDAH2 promoter may act as a protective factor for metabolic syndrome: A case-control study in Azar-Cohort population

Arch Endocrinol Metab. 2021 Nov 3;65(4):443-449. doi: 10.20945/2359-3997000000391. Epub 2021 Jul 16.

Abstract

Objective: Globally developing metabolic syndrome (MetS) prevalence as a major health problem can be related to multiple factors of genetic and environmental. Dimethylaminohydrolase 2 (DDAH2) is the main enzyme implicated in the cardiovascular system, which regulates the nitric oxide pathway. This study investigated the association of DDAH2 polymorphism -499C/G (rs805305) with the risk of MetS among the Azar-Cohort population.

Methods: The occurrence of SNP rs805305 in the DDAH2 gene was tested using the PCR-RFLP method in 332 MetS cases and 294 healthy controls. Afterward, the association of the allele and genotypes with the risk of MetS and its components were examined.

Results: The G allele and GC genotype were significantly associated with a reduced risk of MetS (P ≤ 0.001). Also, the dominant genetic model (GG+GC) significantly decreased the risk of MetS (P = 0.001), however, in sex subtypes MetS risk was significantly reduced in males before and in females after adjustment for age (P ≤ 0.02).

Conclusion: The -499C/G polymorphism of DDAH2 may play a protective role and reduce MetS risk among the Azar-Cohort population.

Keywords: DDAH2; cohort study; metabolic syndrome; polymorphism; rs805305.

MeSH terms

  • Amidohydrolases / genetics*
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease / genetics
  • Genotype
  • Humans
  • Male
  • Metabolic Syndrome* / genetics
  • Polymorphism, Genetic
  • Polymorphism, Single Nucleotide / genetics
  • Promoter Regions, Genetic
  • Protective Factors

Substances

  • Amidohydrolases
  • dimethylargininase

Grants and funding

Funding source: this work was supported by the Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences (No. 64474).